120 related articles for article (PubMed ID: 34600803)
21. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
22. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
23. Out-of-Pocket Costs and Perceived Financial Burden Associated with Prostate Cancer Treatment in a Quebec Remote Area: A Cross-Sectional Study.
El-Haouly A; Lacasse A; El-Rami H; Liandier F; Dragomir A
Curr Oncol; 2020 Nov; 28(1):26-39. PubMed ID: 33704114
[No Abstract] [Full Text] [Related]
24. Patient-Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care.
Hong YR; Salloum RG; Yadav S; Smith G; Mainous AG
Value Health; 2020 Dec; 23(12):1592-1598. PubMed ID: 33248514
[TBL] [Abstract][Full Text] [Related]
25. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.
Bekelman JE; Sylwestrzak G; Barron J; Liu J; Epstein AJ; Freedman G; Malin J; Emanuel EJ
JAMA; 2014 Dec; 312(23):2542-50. PubMed ID: 25494006
[TBL] [Abstract][Full Text] [Related]
26. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
27. Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis.
Brandes A; Koerber F; Schwarzkopf L; Hunger M; Rogowski WH; Waidelich R
BMC Health Serv Res; 2016 Nov; 16(1):664. PubMed ID: 27863486
[TBL] [Abstract][Full Text] [Related]
28. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
29. The burden of out-of-pocket and indirect costs of prostate cancer.
Jayadevappa R; Schwartz JS; Chhatre S; Gallo JJ; Wein AJ; Malkowicz SB
Prostate; 2010 Aug; 70(11):1255-64. PubMed ID: 20658653
[TBL] [Abstract][Full Text] [Related]
30. Total and out-of-pocket costs of different primary management strategies in ovarian cancer.
Suidan RS; He W; Sun CC; Zhao H; Rauh-Hain JA; Fleming ND; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Aug; 221(2):136.e1-136.e9. PubMed ID: 30965052
[TBL] [Abstract][Full Text] [Related]
31. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
32. The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis.
Lindsay D; Schofield P; Nabukalu D; Roberts MJ; Yaxley J; Quinn S; Richards N; Frydenberg M; Gardiner R; Lawrentschuk N; Juraskova I; Murphy DG; Gordon LG
Aust Health Rev; 2024 Feb; 48():172-181. PubMed ID: 38342484
[TBL] [Abstract][Full Text] [Related]
33. A cross-sectional analysis of out-of-pocket expenses for people living with a cancer in rural and outer metropolitan Western Australia.
Slavova-Azmanova NS; Newton JC; Johnson CE; Hohnen H; Ives A; McKiernan S; Platt V; Bulsara M; Saunders C
Aust Health Rev; 2021 Mar; 45(2):148-156. PubMed ID: 33587885
[TBL] [Abstract][Full Text] [Related]
34. Out-of-Pocket Costs for Patients Undergoing Thyroid Surgery.
Zheng F; Huang Y; Wright J; Kuo JH
Ann Surg; 2022 Dec; 276(6):e937-e943. PubMed ID: 34261887
[TBL] [Abstract][Full Text] [Related]
35. Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer.
McDermott CL; Curtis JR; Sun Q; Fedorenko C; Kreizenbeck K; Ramsey SD
J Oncol Pharm Pract; 2022 Jun; 28(4):836-841. PubMed ID: 33823685
[TBL] [Abstract][Full Text] [Related]
36. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
37. The cost of observation care for commercially insured patients visiting the emergency department.
Sabbatini AK; Wright B; Hall MK; Basu A
Am J Emerg Med; 2018 Sep; 36(9):1591-1596. PubMed ID: 29366657
[TBL] [Abstract][Full Text] [Related]
38. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
Lairson DR; Fu S; Chan W; Xu L; Shelal Z; Ramondetta L
Gynecol Oncol; 2017 Apr; 145(1):108-113. PubMed ID: 28196673
[TBL] [Abstract][Full Text] [Related]
39. Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
Stone BV; Laviana AA; Luckenbaugh AN; Huang LC; Zhao Z; Koyama T; Conwill R; Hoffman K; Joyce DD; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
J Urol; 2021 Mar; 205(3):761-768. PubMed ID: 33252300
[TBL] [Abstract][Full Text] [Related]
40. Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada.
Wettstein MS; Palmer KS; Kulkarni GS; Paterson JM; Ling V; Lapointe-Shaw L; Li AH; Brown A; Taljaard M; Ivers N
JAMA Netw Open; 2019 Aug; 2(8):e1910505. PubMed ID: 31469400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
